RCM
BIOTU

Radcliffe Capital Management’s Biotech Acquisition Company Unit BIOTU Stock Holding History

Radcliffe Capital Management’s Portfolio BIOTU Stock Details BIOTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-405,900
Closed -$4.01M – 1007
2021
Q1 		$4.01M Buy
+405,900
New +$4.17M 0.16% 227

Other funds holding BIOTU

AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
HIM
HGC Investment Management Toronto, Ontario, Canada $451M AUM 8.78% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
SRCM
Sage Rock Capital Management New York $22.3M AUM 4.09% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
ACA
Arena Capital Advisors Los Angeles, California $208M AUM 11.42% 1-Year Est. Return
CCM
Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PMAM
Picton Mahoney Asset Management Toronto, Ontario, Canada $13.5B AUM 50.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Radcliffe Capital Management's BIOTU Position: Q2 2021 in Review

Radcliffe Capital Management sold out of Biotech Acquisition Company Unit (BIOTU) in Q2 2021, closing a stake of 405,900 shares — an estimated $4.01M sold.

Radcliffe Capital Management first reported a position in BIOTU in Q1 2021 and held it in 1 quarter. The position peaked at $4.01M in Q1 2021. 41 funds tracked by Wall St. Rank hold BIOTU as of Q2 2021.

  • Radcliffe Capital Management reported no remaining Biotech Acquisition Company Unit position as of Q2 2021 after selling out during the quarter.
  • Radcliffe Capital Management sold 405,900 Biotech Acquisition Company Unit shares in Q2 2021, an estimated $4.01M.
  • Radcliffe Capital Management first reported a position in Biotech Acquisition Company Unit in Q1 2021 and held it in 1 quarter.
  • Radcliffe Capital Management's Biotech Acquisition Company Unit position peaked at $4.01M in Q1 2021.
  • 41 funds tracked by Wall St. Rank held Biotech Acquisition Company Unit as of Q2 2021.

Based on Radcliffe Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.